Document registry — page 17
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
In the population defined for type 2 diabetes mellitus, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate21 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor…
High20 Apr 2026 -
Synthetic ACTH(4-10) analogue heptapeptide. Semax is reported to increase expression of brain-derived neurotrophic factor and its receptor TrkB in rodent hippocampus, and to modulate…
Low19 Apr 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Low17 Apr 2026 -
GLP-1 receptor agonist (exendin-based, short- and extended-release). Exenatide is a naturally DPP-4-resistant GLP-1 receptor agonist. The immediate-release presentation gives short, high peaks that produce a pronounced…
High17 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Apr 2026 -
In the population defined for obesity and overweight in adults, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High15 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Dulaglutide compared with the comparator used in its contributing trials on the anchor…
High14 Apr 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High14 Apr 2026 -
Consultation on the second version of the synthesis of glucagon-like peptide-1 receptor agonists for weight reduction in adults with obesity. The revision re-runs the…
13 Apr 2026 -
Consultation on the draft of CEI-MS-19, which specifies the performance a determination must achieve for chromatographic purity and states what the resulting figure does…
13 Apr 2026 -
Obesity arising from structural hypothalamic injury or a defined genetic syndrome affecting the melanocortin pathway or energy homeostasis.
11 Apr 2026 -
Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?
Moderate08 Apr 2026 -
Peptide active pharmaceutical ingredients and contract development and manufacturing, with a research catalogue of 350+ compounds.
06 Apr 2026 -
Consultation on the draft monograph for Ecnoglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over 40 weeks. The Institute holds no reported primary result for this…
03 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Apr 2026 -
Consultation on the draft monograph for Thymosin beta-4, which the assessment committee released for public comment before ratification. The draft grades the compound's…
29 Mar 2026 -
Consultation on the draft of this analytical evidence review, which registers the question: What is the effect of reconstitution practice on the dose actually delivered…
27 Mar 2026 -
Consultation on the draft monograph for retatrutide, a triple agonist at the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon…
25 Mar 2026 -
Consultation on the draft of this network meta-analysis, which registers the question: In adults with obesity, does a multi-receptor incretin agonist produce a larger…
23 Mar 2026 -
Do incretin-based therapies increase the incidence of acute pancreatitis?
Moderate22 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low22 Mar 2026 -
Consultation on the draft methodological review of transitivity in the incretin network. The review examines whether the trials connecting these interventions through…
20 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
20 Mar 2026 -
Phase 1 ascending dose, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low20 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over 76 weeks. The Institute holds no reported primary result for this record and…
19 Mar 2026 -
Single-arm open-label, phase 3 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low19 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low19 Mar 2026 -
Record of documents ratified in the 2026 Q1 assessment cycle.
18 Mar 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Orforglipron in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
18 Mar 2026 -
Single-arm open-label, phase 3 study of Retatrutide in sleep apnoea over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low18 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Mar 2026 -
Observational, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low16 Mar 2026 -
In the population defined for obesity and overweight in adults, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the…
Moderate13 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over 68 weeks or longer. The Institute holds no reported…
13 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low13 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its…
High11 Mar 2026 -
In the population defined for cutaneous wound healing and tissue repair, is the effect of Thymosin beta-4 maintained across the full duration of the contributing trials?
Low10 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Mar 2026
page 17 of 41